Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Assets Average (2022 - 2025)

Oramed Pharmaceuticals' Assets Average history spans 4 years, with the latest figure at $225.7 million for Q4 2025.

  • For Q4 2025, Assets Average changed N/A year-over-year to $225.7 million; the TTM value through Dec 2025 reached $225.7 million, changed N/A, while the annual FY2023 figure was $191.1 million, N/A changed from the prior year.
  • Assets Average reached $225.7 million in Q4 2025 per ORMP's latest filing, up from $191.1 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $225.7 million in Q4 2023 to a low of $154.6 million in Q2 2025.
  • Average Assets Average over 4 years is $181.4 million, with a median of $171.0 million recorded in 2022.
  • Peak YoY movement for Assets Average: surged 38.45% in 2023, then dropped 26.3% in 2025.
  • A 4-year view of Assets Average shows it stood at $163.0 million in 2022, then soared by 38.45% to $225.7 million in 2023, then decreased by 22.63% to $174.7 million in 2024, then increased by 29.22% to $225.7 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Assets Average are $225.7 million (Q4 2025), $191.1 million (Q3 2025), and $154.6 million (Q2 2025).